IPP&T Magazine Online
News

GSK partners with Canadian firm to produce COVID vaccine


July 8, 2020  


Print this page

The world’s largest vaccine-maker GSK has put its vaccine booster technology to work in a potential new COVID-19 shot, to be developed with a Canadian biopharmaceutical company backed by tobacco company Philip Morris.

Rather than developing its own vaccine in the global race to combat the pandemic, GSK has instead focused on contributing its adjuvant technology to at least seven other global companies, including Sanofi and China’s Clover.

The latest deal, with Canadian firm Medicago – according to Reuters – uses plant-based technology that differs from GSK’s other coronavirus-partnerships and boosts the London-listed company’s chances of finding a successful candidate and scaling production relatively quickly.

There are no approved vaccines for the respiratory illness caused by the new coronavirus, but 19 vaccines are being trialled in humans globally and some treatments, such as Gilead’s remdesivir, have been approved in certain regions.

Advertisment

Medicago’s approach, already used in a flu vaccine awaiting Canadian approval, takes the leaves of a plant as bioreactors to produce one of the three spike proteins of the novel coronavirus, the S-spike, which can be then used in the vaccine with GSK’s adjuvant.

GSK said the companies aimed to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021. An early-stage human trial of three different dosage levels is expected to begin in mid-July.

(Reuters)


Print this page

Related


Leave a Reply

Your email address will not be published. Required fields are marked *

*